Cargando…
Phase IIb study of pembrolizumab combined with S‐1 + oxaliplatin or S‐1 + cisplatin as first‐line chemotherapy for gastric cancer
The KEYNOTE‐659 study evaluated the efficacy and safety of first‐line pembrolizumab plus S‐1 and oxaliplatin (SOX) (cohort 1) or S‐1 and cisplatin (SP) (cohort 2) for advanced gastric/gastroesophageal junction (G/GEJ) cancer in Japan. Herein, we update the results of cohort 1 and describe the result...
Autores principales: | Yamaguchi, Kensei, Minashi, Keiko, Sakai, Daisuke, Nishina, Tomohiro, Omuro, Yasushi, Tsuda, Masahiro, Iwagami, Shiroh, Kawakami, Hisato, Esaki, Taito, Sugimoto, Naotoshi, Oshima, Takashi, Kato, Ken, Amagai, Kenji, Hosaka, Hisashi, Komine, Keigo, Yasui, Hisateru, Negoro, Yuji, Ishido, Kenji, Tsushima, Takahiro, Han, Shirong, Shiratori, Shinichi, Takami, Tomoko, Shitara, Kohei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357620/ https://www.ncbi.nlm.nih.gov/pubmed/35701865 http://dx.doi.org/10.1111/cas.15462 |
Ejemplares similares
-
Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer
por: Muro, Kei, et al.
Publicado: (2023) -
Cancer-related FGFR2 overexpression and gene amplification in Japanese patients with gastric cancer
por: Minashi, Keiko, et al.
Publicado: (2021) -
A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients
por: Hamaguchi, Tetsuya, et al.
Publicado: (2018) -
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2)
por: Kato, Ken, et al.
Publicado: (2018) -
Sex differences in the safety of S‐1 plus oxaliplatin and S‐1 plus cisplatin for patients with metastatic gastric cancer
por: Yamada, Yasuhide, et al.
Publicado: (2019)